The potential use of Disulfiram as a pan-ALDH1 inhibitor was highlighted in a recent Phase IIb trial, in which Disulfiram in combination with cisplatin and vinorelbine was examined in the treatment of metastatic NSCLC patients. The gene discussed is ALDH1A1; the disease is non-small cell lung carcinoma.